# Anteris Technologies Global Corp.: financial statements, quarterly

AVR · Nasdaq · CIK 2011514 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/avr.md) · [Financials](/companies/avr/financials.md) · [Filings](/companies/avr/filings.md) · [Insiders](/companies/avr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/avr/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.8](/filings/0001140361-25-018701.md) | [0.6](/filings/0001140361-25-030146.md) | [0.8](/filings/0001140361-25-041643.md) | [0.5 d](/filings/0001140361-26-006977.md) | [0.6](/filings/0001140361-26-020806.md) | [0.6](/filings/0001140361-26-032232.md) | [0.4](/filings/0001140361-25-041643.md) | [0.3 d](/filings/0001140361-26-006977.md) | [0.5](/filings/0001140361-26-020806.md) | [1.0](/filings/0001140361-26-032232.md) |
| Cost of revenue | $m | [0.5](/filings/0001140361-25-018701.md) | [0.3](/filings/0001140361-25-030146.md) | [0.4](/filings/0001140361-25-041643.md) | [0.2 d](/filings/0001140361-26-006977.md) | [0.2](/filings/0001140361-26-020806.md) | [0.1](/filings/0001140361-26-032232.md) | [0.1](/filings/0001140361-25-041643.md) | [0.1 d](/filings/0001140361-26-006977.md) | [0.1](/filings/0001140361-26-020806.md) | [0.2](/filings/0001140361-26-032232.md) |
| Research and development | $m | [11.6](/filings/0001140361-25-018701.md) | [12.6](/filings/0001140361-25-030146.md) | [13.9](/filings/0001140361-25-041643.md) | [13.3 d](/filings/0001140361-26-006977.md) | [16.5](/filings/0001140361-26-020806.md) | [16.3](/filings/0001140361-26-032232.md) | [16.8](/filings/0001140361-25-041643.md) | [19.5 d](/filings/0001140361-26-006977.md) | [17.5](/filings/0001140361-26-020806.md) | [23.4](/filings/0001140361-26-032232.md) |
| Selling, general and administrative | $m | [6.5](/filings/0001140361-25-018701.md) | [6.2](/filings/0001140361-25-030146.md) | [7.0](/filings/0001140361-25-041643.md) | [8.5 d](/filings/0001140361-26-006977.md) | [5.7](/filings/0001140361-26-020806.md) | [5.0](/filings/0001140361-26-032232.md) | [5.8](/filings/0001140361-25-041643.md) | [9.7 d](/filings/0001140361-26-006977.md) | [6.9](/filings/0001140361-26-020806.md) | [8.4](/filings/0001140361-26-032232.md) |
| Operating income | $m | [(17.8)](/filings/0001140361-25-018701.md) | [(18.5)](/filings/0001140361-25-030146.md) | [(20.6)](/filings/0001140361-25-041643.md) | [(21.5) d](/filings/0001140361-26-006977.md) | [(21.8)](/filings/0001140361-26-020806.md) | [(20.9)](/filings/0001140361-26-032232.md) | [(22.3)](/filings/0001140361-25-041643.md) | [(29.0) d](/filings/0001140361-26-006977.md) | [(24.0)](/filings/0001140361-26-020806.md) | [(31.0)](/filings/0001140361-26-032232.md) |
| Income tax | $m | [0.0](/filings/0001140361-25-018701.md) | [0.0](/filings/0001140361-25-030146.md) | [0.0](/filings/0001140361-25-041643.md) | [0.0 d](/filings/0001140361-26-006977.md) | [0.0](/filings/0001140361-26-020806.md) | [0.0](/filings/0001140361-26-032232.md) | [0.0](/filings/0001140361-25-041643.md) | [0.0 d](/filings/0001140361-26-006977.md) | [0.5](/filings/0001140361-26-020806.md) | [0.0](/filings/0001140361-26-032232.md) |
| Net income | $m | [(16.4)](/filings/0001140361-25-018701.md) | [(18.7)](/filings/0001140361-25-030146.md) | [(21.9)](/filings/0001140361-25-041643.md) | [(19.4) d](/filings/0001140361-26-006977.md) | [(21.9)](/filings/0001140361-26-020806.md) | [(20.8)](/filings/0001140361-26-032232.md) | [(22.2)](/filings/0001140361-25-041643.md) | [(29.2) d](/filings/0001140361-26-006977.md) | [(23.0)](/filings/0001140361-26-020806.md) | [(29.1)](/filings/0001140361-26-032232.md) |
| Diluted EPS | $ per share | [(0.91)](/filings/0001140361-25-018701.md) | [(0.98)](/filings/0001140361-25-030146.md) | [(1.07)](/filings/0001140361-25-041643.md) | not reported | [(0.61)](/filings/0001140361-26-020806.md) | [(0.58)](/filings/0001140361-26-032232.md) | [(0.62)](/filings/0001140361-25-041643.md) | not reported | [(0.28)](/filings/0001140361-26-020806.md) | [(0.30)](/filings/0001140361-26-032232.md) |
| Basic EPS | $ per share | [(0.91)](/filings/0001140361-25-018701.md) | [(0.98)](/filings/0001140361-25-030146.md) | [(1.07)](/filings/0001140361-25-041643.md) | not reported | [(0.61)](/filings/0001140361-26-020806.md) | [(0.58)](/filings/0001140361-26-032232.md) | [(0.62)](/filings/0001140361-25-041643.md) | not reported | [(0.28)](/filings/0001140361-26-020806.md) | [(0.30)](/filings/0001140361-26-032232.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | [70.5](/filings/0001140361-25-018701.md) | [49.0](/filings/0001140361-25-018701.md) | not reported | not reported | [6.7](/filings/0001140361-26-032232.md) | [31.7](/filings/0001140361-26-020806.md) | [250](/filings/0001140361-26-032232.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | [74.7](/filings/0001140361-26-006977.md) | [53.0](/filings/0001140361-25-018701.md) | [32.2](/filings/0001140361-25-030146.md) | [11.2](/filings/0001140361-25-041643.md) | [15.7](/filings/0001140361-26-032232.md) | [287](/filings/0001140361-26-020806.md) | [261](/filings/0001140361-26-032232.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | [80.7](/filings/0001140361-26-006977.md) | [58.8](/filings/0001140361-25-018701.md) | [39.9](/filings/0001140361-25-030146.md) | [19.1](/filings/0001140361-25-041643.md) | [23.0](/filings/0001140361-26-032232.md) | [295](/filings/0001140361-26-020806.md) | [273](/filings/0001140361-26-032232.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [16.6](/filings/0001140361-26-006977.md) | [14.4](/filings/0001140361-25-018701.md) | [13.3](/filings/0001140361-25-030146.md) | [13.4](/filings/0001140361-25-041643.md) | [21.4](/filings/0001140361-26-032232.md) | [13.7](/filings/0001140361-26-020806.md) | [18.4](/filings/0001140361-26-032232.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | [18.0](/filings/0001140361-26-006977.md) | [15.7](/filings/0001140361-25-018701.md) | [15.8](/filings/0001140361-25-030146.md) | [15.7](/filings/0001140361-25-041643.md) | [23.3](/filings/0001140361-26-032232.md) | [16.3](/filings/0001140361-26-020806.md) | [20.8](/filings/0001140361-26-032232.md) |
| Shareholders' equity | $m | [18.9](/filings/0001140361-26-006977.md) | [4.4](/filings/0001140361-25-041643.md) | [2.6](/filings/0001140361-25-041643.md) | [2.9](/filings/0001140361-25-041643.md) | [62.8](/filings/0001140361-26-006977.md) | [43.3](/filings/0001140361-25-018701.md) | [24.4](/filings/0001140361-25-030146.md) | [3.7](/filings/0001140361-25-041643.md) | [(0.1)](/filings/0001140361-26-032232.md) | [278](/filings/0001140361-26-020806.md) | [251](/filings/0001140361-26-032232.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(15.5)](/filings/0001140361-25-018701.md) | [(13.4) d](/filings/0001140361-25-030146.md) | [(14.1) d](/filings/0001140361-25-041643.md) | [(18.2) d](/filings/0001140361-26-006977.md) | [(21.5)](/filings/0001140361-26-020806.md) | [(19.5) d](/filings/0001140361-26-032232.md) | [(18.3) d](/filings/0001140361-25-041643.md) | [(18.5) d](/filings/0001140361-26-006977.md) | [(28.7)](/filings/0001140361-26-020806.md) | [(20.8) d](/filings/0001140361-26-032232.md) |
| Capital expenditure | $m | [0.7](/filings/0001140361-25-018701.md) | [0.6 d](/filings/0001140361-25-030146.md) | [0.5 d](/filings/0001140361-25-041643.md) | [0.4 d](/filings/0001140361-26-006977.md) | [0.2](/filings/0001140361-26-020806.md) | [0.5 d](/filings/0001140361-26-032232.md) | [0.8 d](/filings/0001140361-25-041643.md) | [0.4 d](/filings/0001140361-26-006977.md) | [0.1](/filings/0001140361-26-020806.md) | [0.6 d](/filings/0001140361-26-032232.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [17.9](/filings/0001140361-25-018701.md) | [19.0](/filings/0001140361-25-030146.md) | [20.5](/filings/0001140361-25-041643.md) | [36.0](/filings/0001140361-26-020806.md) | [36.1](/filings/0001140361-26-032232.md) | [36.1](/filings/0001140361-25-041643.md) | [83.0](/filings/0001140361-26-020806.md) | [97.3](/filings/0001140361-26-032232.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 97,458,474 at 2026-08-10, from the cover of the [10-Q filed 2026-08-11](/filings/0001140361-26-032232.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.